drugset / Trial / NCT00936234
Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).
RandomizedCrossoverQuadruple-blindBasic science
Summary
SDF-1, an important cytokine for neovascularisation is cleaved by (dipeptidyl peptidase IV) DPPIV. The aim of this study is to assess the effect of the dipeptidyl peptidase IV inhibitor vildagliptin (Galvus®) on endothelial function as well as number and functional activity of progenitor cells in patients with documented diabetes mellitus.
Timeline
- Start
- 2009-07
- Primary completion
- 2011-09
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Vildagliptin | Other / unclassified | 50 mg | Oral |
Indications
No indication recorded.